[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100647916":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":15,"locations":21,"responsibleParty":39,"collaborators":10,"id":42,"slug":43,"hasResults":44,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":44,"sex":50,"minAge":51,"maxAge":10,"enrollmentInfo":52,"targetDuration":55,"studyType":56,"phases":10,"briefSummary":57,"conditions":58,"keywords":64,"overallStatus":24,"whyStopped":10,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},{"fullName":5,"class":6},"Qianfoshan Hospital","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"ABPA Exacerbation Group",null,"All subjects met the 2024 ISHAM consensus diagnostic criteria for allergic bronchopulmonary aspergillosis. An ABPA exacerbation was defined based on the official ISHAM 2024 criteria: patients with established ABPA presenting with sustained clinical worsening for over 14 days or radiological deterioration, accompanied by a ≥50% elevation in serum total IgE compared to the stable baseline level, after ruling out alternative causes of disease flare. Those who developed an ABPA exacerbation satisfying the above definition within one year of study entry were assigned to the ABPA exacerbation group.",{"label":13,"type":10,"description":14,"interventionNames":10},"Non-exacerbation Group","All subjects fulfilled the 2024 ISHAM consensus diagnostic criteria for allergic bronchopulmonary aspergillosis, and those without any ABPA flare meeting the above exacerbation definition within one year after study entry were assigned to the non-exacerbation group.",[16],{"name":17,"role":18,"phone":19,"phoneExt":10,"email":20},"Qian Qi","CONTACT","+86 13706380314","qiqianqlh@163.com",[22],{"facility":23,"status":24,"city":25,"state":26,"zip":27,"country":28,"countryCode":29,"cosmosGeoPoint":30,"geoPoint":35,"contacts":36},"Department of Respiratory, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, #16766, Jingshi Road, Jinan City, Shandong Province, China","RECRUITING","Jinan","Shandong","250014","China","CN",{"type":31,"coordinates":32},"Point",[33,34],116.99722,36.66833,{"lat":34,"lon":33},[37],{"name":10,"role":18,"phone":38,"phoneExt":10,"email":20},"13706380314",{"type":40,"investigatorFullName":17,"investigatorTitle":41,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Prof.","100647916","ml-based-abpa-recurrence-prediction-and-clinical-utility-100647916",false,"NCT07714863","ML-Based ABPA Recurrence Prediction and Clinical Utility","Machine Learning-Based Prediction of Recurrence Risk in Allergic Bronchopulmonary Aspergillosis and Its Clinical Decision-Making Value: A Multicenter Study With External Validation","ABPA-ML","Inclusion Criteria:\n\n1. Aged between 18 and 80 years old.\n2. Consistent with the diagnostic consensus criteria for ABPA proposed by the ISHAM-ABPA Working Group.\n3. Patients in stable phase of ABPA: newly diagnosed treatment-naive patients or those with prior ABPA exacerbation who achieved at least 50% improvement in symptoms assessed by Likert scale or visual analogue scale (VAS) following initial therapy, accompanied by marked radiological improvement (≥50% reduction in pulmonary opacities) or a minimum 20% decline in serum total IgE level.\n\nExclusion Criteria:\n\n1. Concurrent malignant tumors or severe organ dysfunction involving the heart, brain, kidney and other vital organs.\n2. Complicated with severe underlying diseases, including active pulmonary tuberculosis, lung cancer, chronic heart failure (NYHA class Ⅳ), chronic kidney disease stage 5 (CKD 5), decompensated liver cirrhosis, etc.\n3. Immunocompromised status, such as human immunodeficiency virus (HIV) infection, long-term oral administration of glucocorticoids or immunosuppressive agents.\n4. Pregnant or breastfeeding women.\n5. Patients with missing core clinical data or incomplete medical records.","ALL","18 Years",{"count":53,"type":54},200,"ESTIMATED","1 Year","OBSERVATIONAL","This multicenter bidirectional cohort study aims to develop and externally validate a machine learning model for predicting the risk of acute exacerbation within 1 year in patients with allergic bronchopulmonary aspergillosis (ABPA) during the stable phase, and further to evaluate the model's practical value in risk stratification and clinical decision-making.\n\nAll patients diagnosed with ABPA according to the ISHAM 2024 criteria will be assigned to either the acute exacerbation group or the non-exacerbation group based on whether they experience an acute exacerbation within 1 year. Enrolled participants will be randomly divided into a training set and an internal validation set. During the feature selection phase, univariate analysis, collinearity diagnostics, feature importance ranking derived from nine machine learning algorithms, and expert consensus are comprehensively applied, ultimately leading to the development of 12 independent machine learning models.\n\nModel performance is assessed using the receiver operating characteristic (ROC) curve and its area under the curve (AUC), sensitivity, specificity, F1-score, calibration curve, and decision curve analysis. In addition, external validation further enhances the credibility of the model. To improve clinical interpretability, the SHAP method is employed to quantify the contribution of each feature, and an interactive nomogram is constructed to facilitate clinical application.\n\nAll participants will be followed up for 12 months, during which regular clinical and laboratory evaluations will be performed.",[59,60,61,62,63],"ABPA","Allergic Bronchopulmonary Aspergillosis","Allergic Bronchopulmonary Aspergillosis (ABPA)","Acute Exacerbation","Machine Learning",[59,65,63],"Acute exacerbation","2026-07-14",{"date":68,"type":69},"2026-07-20","ACTUAL",{"date":71,"type":69},"2021-01-01",{"date":73,"type":54},"2028-12-31",{"name":5,"class":6},1]